^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IFx-2.0

    i
    Other names: IFx-2.0, IFx-Hu2.0, pAc/emm55, autologous whole-cell ImmuneFx cancer vaccine, emm55 Streptococcal antigen pDNA, pDNA intralesional cancer vaccine
    Associations

    News

    Trials
    Company:
    TuHURA Bio
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    3ms
    Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers (clinicaltrials.gov)
    P1, N=23, Completed, TuHURA Biosciences, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    IFx-2.0
    5ms
    Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, TuHURA Biosciences, Inc. | Trial completion date: Mar 2024 --> Aug 2024
    Trial completion date • Metastases
    |
    IFx-2.0
    10ms
    Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, TuHURA Biosciences, Inc. | Trial completion date: Dec 2023 --> Mar 2024 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Metastases
    |
    IFx-2.0
    1year
    Immune priming IFx-Hu2.0 promotes antibody responses necessary for anti-PD1 responses in PD-1 refractory melanoma patients (SITC 2023)
    "Conclusions Antigenic Emm55-derived peptides provoke individual immune responses via an antigen/interferon-dependent process in those patients with the longest survival after subsequent anti-PD1 treatment. Subsequent studies are being planned for the clinic."
    Clinical
    |
    nCounter® PanCancer IO 360™ Panel
    |
    IFx-2.0
    4years
    Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model. (PubMed, Cancer Immunol Immunother)
    pAc/emm55 treatment combined with PD-1 blockade enhanced anti-tumor immune response and improved systemic anti-tumor immunity. Together, these strategies may lead to improvements in the treatment of patients with melanoma.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    IFx-2.0
    over4years
    [VIRTUAL] Trial in progress: IFx-Hu2.0 (plasmid DNA coding for Emm55 streptococcal antigen in a cationic polymer) phase I first in human study for unresectable stage III or stage IV cutaneous melanoma (AACR-I 2020)
    Success of the study is defined as being able to treat 5/6 subjects without DLT at 28 days. Three of the six planned trial subjects have been enrolled as of January 2020 (Clinical trial registry number: NCT03655756).
    P1 data
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8) • SOX10 (SRY-Box 10) • FOXP3 (Forkhead Box P3)
    |
    IFx-2.0